Tuberculous pleurisy diagnosed by medical thoracoscopy in an adalimumab-treated rheumatoid arthritis patient after treatment of latent tuberculosis infection

REFERENCES

• McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–19.
   PubMed Web of Science ®Google Scholar
• Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762–84.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the man-agement of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010; 69(6) : 964–75.
   Google Scholar
• Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Coster L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 2005;52(7):1986–92.
   PubMed Web of Science ®Google Scholar
• Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65(7): 889–94.
   PubMed Web of Science ®Google Scholar
• Keystone EC, Papp KA, Wobeser W. Challenges in diagnosing latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. J Rheumatol. 2011;38(7):1234–43.
   Google Scholar
• Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum. 2010;62(9): 2569–81.
   Google Scholar
• Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011;70 (3):404–13.
   PubMed Web of Science ®Google Scholar
• Sakuraba M, Masuda K, Hebisawa A, Sagara Y, Komatsu H. Thoracoscopic pleural biopsy for tuberculous pleurisy under local anesthesia. Ann Thorac Cardiovasc Surg. 2006;12(4):245–8.
   PubMedGoogle Scholar
• Pereira JM, Madureira AJ, Vieira A, Ramos I. Abdominal tuberculosis: imaging features. Eur J Radiol. 2005;55(2):173–80.
   PubMed Web of Science ®Google Scholar
• Mohan AK, Cote TR, Block JA, Manadan AM, Siegel JN, Braun MM. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis. 2004;39(3):295–9.
   PubMed Web of Science ®Google Scholar
• Gopi A, Madhavan SM, Sharma SK, Sohn SA. Diagnosis and treatment of tuberculous pleural effusion in 2006. Chest. 2007; 131(3):880–9.
   PubMed Web of Science ®Google Scholar
• Ogata Y, Aoe K, Hiraki A, Murakami K, Kishino D, Chikamori K, et al. Is adenosine deaminase in pleural fluid a useful marker for differentiating tuberculosis from lung cancer or mesothelioma in Japan, a country with intermediate incidence of tuberculosis? Acta Med Okayama. 2011;65(4):259–63.
   PubMedGoogle Scholar
• Deana I, Ribero. E, Martinez-Vazquez JM, Ruiz I, Bejarano E, Pigrau C, et al. Adenosine deaminase activity in rheumatoid pleural effusion. Ann Rheum Dis. 1988;47(5):394–7.
   PubMedGoogle Scholar
• Diacon AH, Van de Wal BW, Wyser C, Smedema JP, Bezu-idenhout J, Bolliger CT, et al. Diagnostic tools in tuberculous pleurisy: a direct comparative study. Eur Respir J. 2003;22(4): 589–91.
   Google Scholar
• Michaud G, Berkowitz DM, Ernst A. Pleuroscopy for diagnosis and therapy for pleural effusions. Chest. 2010;138(5):1242–6.
   Google Scholar
• Parra Ruiz J, Ortego Centeno N, Raya Alvarez E. Development of tuberculosis in a patient treated with infliximab who had received prophylactic therapy with isoniazid. J Rheumatol. 2003;30(7):1657–8.
   PubMedGoogle Scholar
• Sichletidis L, Settas L, Spyratos D, Chloros D, Patakas D. Tuberculosis in patients receiving anti-TNF agents despite che-moprophylaxis. Int J Tuberc Lung Dis. 2006;10(10):1127–32.
   PubMed Web of Science ®Google Scholar
• Hirano Y, Kojima T, Kanayama Y, Ishikawa H, Ishiguro N. A case of lung tuberculosis in a patient with rheumatoid arthritis treated with infliximab after antituberculosis chemoprophylaxis with isoniazid. Mod Rheumatol. 2009;19(3):323–8.
   Google Scholar
• Nobre CA, Callado MR, Lima JR, Gomes KW, Martiniano GV, Vieira WP. Tuberculosis infection in rheumatic patients with infliximab therapy: experience with 157 patients. Rheumatol Int. 2011.
   Google Scholar
• Gomez-Reino JJ, Carmona L, Angel Descalzo M, Biobadaser Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum. 2007;57(5): 756–61.
   Google Scholar
• Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, et al. Safety and effectiveness of adalimumab in Japanese rheu-matoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumatol. 2011.
   Google Scholar
• Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, Montero D, Pascual-Gomez E, Mola EM, et al. Effectiveness of recom-mendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 2005;52(6):1766–72.
   PubMed Web of Science ®Google Scholar
• Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA. 1999;281(11):1014–8.
   Google Scholar
• Grant AD, Mngadi KT, van Halsema CL, Luttig MM, Fielding KL, Churchyard GJ. Adverse events with isoniazid preventive therapy: experience from a large trial. AIDS. 2010;24(Suppl 5):S29–36.
   Google Scholar
• Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and iso-niazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155–66.
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Recom-mendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2011;60(48):1650–3.
   PubMedGoogle Scholar